次世代エネルギー産業・グリーン経済の国際リサーチ情報サイト

再生医療の世界市場:タイプ別、用途別2024年予測

Regenerative Medicine Market by Type [Cell-Based Immunotherapy & Cell Therapy (Allogeneic & Autologous Products), Tissue Engineering, Gene Therapy], Applications (Wounds & Dermal, Musculoskeletal, Oncology), Region - Global Forecast to 2024

出版元:MarketsandMarketsLinkIcon出版元について
発行年:2019年 3月
定価 Single User License(1名様ライセンス)US$5,650(米国ドル)/Multi User License(5名様)$6,650 /Corporate User License $8,150
ご予算に応じた各種ご提案も承ります。詳細はお問い合わせください。
ご請求は円換算(お見積り日TTSレート)となります。
納品形態:PDF by Email
当調査レポートは英文108 ページになります。
商品コード:MAM1500

お問い合わせ、お見積りのリクエストは下のボタンをクリックしてご入力ください。



【レポート紹介】
再生医療の世界市場規模は2019年で推計133億ドル、今後2024年には387億ドルに達するとレポートでは予測しています。当レポートでは、2024年に至る再生医療の世界市場予測(市場規模US$)、タイプ別市場(セルベース免疫療法/細胞治療製品、ティッシュエンジニアリング、遺伝子治療製品)、用途別市場(筋骨格障害、創傷ケア、腫瘍学、眼疾患、糖尿病、その他)、主要国地域別市場など、詳細な市場予測データと分析を掲載しています。また市場分析、競合状況、主要メーカー企業10社プロフィール動向などの情報も交えて、再生医療市場の現在と今後展開を予測分析していきます。

【レポート構成概要】
◆再生医療の世界市場予測2017-2024年
・市場規模(US$)

◆タイプ別、市場-2024年
セルベース免疫療法/細胞治療製品
・同種異系製品
・自己製品
ティッシュエンジニアリング
遺伝子治療製品
※(市場規模US$)

◆用途別、市場-2024年
・筋骨格障害
・創傷ケア
・腫瘍学
・眼疾患
・糖尿病
・その他
※(市場規模US$)

◆主要国地域別市場-2024年
北米
・米国、カナダ
欧州
・英国、ドイツ、フランス
・その他欧州
アジア太平洋
・日本、中国、オーストラリア
・その他アジア太平洋
その他地域
※国地域別に、全セグメント別の細分化データ掲載、詳細は目次参照

◆市場分析
・市場ダイナミクス(ドライバー、障壁、機会)
・競合状況

◆再生医療の主要企業プロフィール動向
・NOVARTIS AG             
・VERICEL        
・INTEGRA LIFESCIENCES         
・MIMEDX GROUP        
・STRYKER       
・WRIGHT MEDICAL    
・SPARK THERAPEUTICS           
・OSIRIS THERAPEUTICS           
・KITE PHARMA (SUBSIDIARY OF GILEAD SCIENCES)   
・ORGANOGENESIS

(全108頁)



【レポート詳細目次、データ項目一覧は当ページ下を参照ください】

英文詳細目次(table of contents)

【原文詳細目次】

Regenerative Medicine Market by Type [Cell-Based Immunotherapy & Cell Therapy (Allogeneic & Autologous Products), Tissue Engineering, Gene Therapy], Applications (Wounds & Dermal, Musculoskeletal, Oncology), Region - Global Forecast to 2024

Table of Contents

1.... INTRODUCTION

1.1            OBJECTIVES OF THE STUDY
1.2            MARKET DEFINITION
1.2.1               MARKETS COVERED.. 14
1.2.2               YEARS CONSIDERED FOR THE STUDY
1.3            CURRENCY
1.4            LIMITATIONS
1.5            STAKEHOLDERS

2.... RESEARCH METHODOLOGY

2.1            SECONDARY DATA
2.1.1               KEY DATA FROM SECONDARY SOURCES
2.2            PRIMARY DATA
2.2.1               KEY DATA FROM PRIMARY SOURCES
2.3            MARKET SIZE ESTIMATION
2.3.1               BOTTOM-UP APPROACH
2.3.2               TOP-DOWN APPROACH.. 20
2.4            MARKET BREAKDOWN AND DATA TRIANGULATION
2.5            ASSUMPTIONS FOR THE STUDY

3.... EXECUTIVE SUMMARY

4.... PREMIUM INSIGHTS

4.1            REGENERATIVE MEDICINE: MARKET OVERVIEW
4.2            REGENERATIVE MEDICINE MARKET, BY TYPE & APPLICATION (2019)
4.3            GEOGRAPHICAL SNAPSHOT OF THE REGENERATIVE MEDICINE MARKET

5.... MARKET OVERVIEW

5.1            INTRODUCTION
5.2            CLINICAL TRIALS FOR REGENERATIVE MEDICINE
5.3            MARKET DYNAMICS
5.3.1               DRIVERS
5.3.1.1             RISING PREVALENCE OF CHRONIC DISEASES AND GENETIC DISORDERS
5.3.1.2             RISING GOVERNMENT INVESTMENTS IN REGENERATIVE MEDICINE RESEARCH.. 32
5.3.1.3             PRODUCT APPROVALS AND GROWING PIPELINE OF REGENERATIVE MEDICINE PRODUCTS

5.3.2               RESTRAINTS
5.3.2.1             ETHICAL CONCERNS RELATED TO THE USE OF EMBRYONIC STEM CELLS IN RESEARCH & DEVELOPMENT
5.3.3               OPPORTUNITIES
5.3.3.1             IMPLEMENTATION OF THE 21ST CENTURY CURES ACT
5.3.3.2             RISING DEMAND FOR ORGAN TRANSPLANTATION

6.... REGENERATIVE MEDICINE MARKET, BY TYPE

6.1            INTRODUCTION
6.2            CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS
6.2.1               ALLOGENEIC PRODUCTS
6.2.2               AUTOLOGOUS PRODUCTS
6.3            TISSUE-ENGINEERED PRODUCTS
6.4            GENE THERAPY PRODUCTS

7.... REGENERATIVE MEDICINE MARKET, BY APPLICATION

7.1            INTRODUCTION
7.2            MUSCULOSKELETAL DISORDERS
7.2.1               MUSCULOSKELETAL DISORDERS SEGMENT WILL CONTINUE TO DOMINATE THE REGENERATIVE MEDICINE MARKET IN 2024
7.3            WOUND CARE
7.3.1               INCREASING PREVALENCE OF TARGET CONDITIONS TO DRIVE THE GROWTH OF THIS APPLICATION SEGMENT
7.4            ONCOLOGY
7.4.1               INCREASING PREVALENCE OF CANCER TO SUPPORT MARKET GROWTH
7.5            OCULAR DISORDERS
7.5.1               GROWING NUMBER OF PRODUCT APPROVALS TO SUPPORT MARKET GROWTH
7.6            DIABETES
7.6.1               INCREASING INCIDENCE OF DIABETES AND THE GROWING FOCUS OF COMPANIES ON DEVELOPING REGENERATIVE MEDICINE FOR THE TREATMENT OF DIABETES ARE THE KEY FACTORS DRIVING MARKET GROWTH
7.7            OTHER APPLICATIONS

8.... REGENERATIVE MEDICINE MARKET, BY REGION

8.1            INTRODUCTION
8.2            NORTH AMERICA
8.2.1               US
8.2.1.1             US ACCOUNTS FOR THE LARGEST SHARE OF THE REGENERATIVE MEDICINE MARKET IN NORTH AMERICA
8.2.2               CANADA
8.2.2.1             INCREASING R&D FUNDING FOR REGENERATIVE MEDICINE IS A KEY FACTOR INFLUENCING THE GROWTH OF THE CANADIAN REGENERATIVE MEDICINE MARKET

8.3            EUROPE
8.3.1               UK
8.3.1.1             UK ACCOUNTS FOR THE LARGEST MARKET SHARE IN THE EUROPEAN MARKET
8.3.2               GERMANY
8.3.2.1             GERMANY HAS A STRONG FOUNDATION FOR R&D, INCLUDING OVER 1,000 PUBLIC AND PRIVATE INSTITUTIONS
8.3.3               FRANCE
8.3.3.1             RISING R&D EXPENDITURE, A MAJOR GROWTH DRIVER IN FRANCE
8.3.4               REST OF EUROPE
8.4            ASIA PACIFIC
8.4.1               JAPAN
8.4.1.1             COMPARATIVELY LENIENT REGULATIONS AND RISING GERIATRIC POPULATION WILL DRIVE MARKET GROWTH
8.4.2               CHINA
8.4.2.1             FAVORABLE INVESTMENTS AND GOVERNMENT SUPPORT WILL CONTRIBUTE TO THE GROWTH OF THE CHINESE MARKET
8.4.3               AUSTRALIA
8.4.3.1             STRONG RESEARCH BASE AND AVAILABILITY OF FUNDS WILL PUSH MARKET GROWTH IN AUSTRALIA
8.4.4               ROAPAC
8.5            REST OF THE WORLD

9.... COMPETITIVE LANDSCAPE

9.1            OVERVIEW
9.2            MARKET RANKING ANALYSIS, 2017
9.3            KEY STRATEGIES
9.3.1               PRODUCT LAUNCHES
9.4            COMPETITIVE LEADERSHIP MAPPING (2018)
9.4.1               VENDOR INCLUSION CRITERIA
9.4.2               VISIONARY LEADERS. 82
9.4.3               INNOVATORS
9.4.4               DYNAMIC DIFFERENTIATORS
9.4.5               EMERGING COMPANIES
9.5            COMPETITIVE LEADERSHIP MAPPING FOR START-UPS (2018)
9.5.1               PROGRESSIVE COMPANIES
9.5.2               STARTING BLOCKS. 84
9.5.3               RESPONSIVE COMPANIES
9.5.4               DYNAMIC COMPANIES. 84

10.. COMPANY PROFILES

(INTRODUCTION, PRODUCTS & SERVICES, STRATEGY, & ANALYST INSIGHTS, DEVELOPMENTS, MNM VIEW)*
10.1          NOVARTIS AG
10.2          VERICEL
10.3          INTEGRA LIFESCIENCES
10.4          MIMEDX GROUP
10.5          STRYKER
10.6          WRIGHT MEDICAL
10.7          SPARK THERAPEUTICS
10.8          OSIRIS THERAPEUTICS
10.9          KITE PHARMA (SUBSIDIARY OF GILEAD SCIENCES)
10.10       ORGANOGENESIS

*DETAILS ON MARKETSANDMARKETS VIEW, INTRODUCTION, PRODUCT & SERVICES, STRATEGY, & ANALYST INSIGHTS, NEW DEVELOPMENTS MIGHT NOT BE CAPTURED IN CASE OF UNLISTED COMPANIES.
11.. APPENDIX
11.1          INSIGHTS FROM INDUSTRY EXPERTS
11.2          DISCUSSION GUIDE
11.3          AVAILABLE CUSTOMIZATIONS
11.4          RELATED REPORTS
11.5          AUTHOR DETAILS

LIST OF TABLES

TABLE 1               FEW IMPORTANT CLINICAL STUDIES IN THE REGENERATIVE MEDICINE MARKET
TABLE 2               CANCER INCIDENCE AND MORTALITY, BY REGION, 2012–2035
TABLE 3               FUNDING FOR REGENERATIVE MEDICINE RESEARCH
BY THE NIH UNDER THE 21ST CENTURY CURES ACT  32
TABLE 4               NIH FUNDING FOR REGENERATIVE MEDICINE RESEARCH IN THE US,
2014–2016 (USD MILLION)
TABLE 5               CALIFORNIA INSTITUTE OF REGENERATIVE MEDICINE FUNDING FOR REGENERATIVE MEDICINE RESEARCH
TABLE 6               NUMBER OF COMPANIES OPERATING IN THE REGENERATIVE MEDICINE MARKET, BY REGION (2014–2018)
TABLE 7               REGENERATIVE MEDICINE MARKET, BY TYPE, 2017–2024 (USD BILLION)
TABLE 8               FEW OF THE COMMERCIALIZED CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS
TABLE 9               CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS MARKET,
BY REGION, 2017–2024 (USD BILLION)
TABLE 10             CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS MARKET,
BY TYPE, 2017–2024 (USD BILLION)
TABLE 11             CELL-BASED ALLOGENEIC REGENERATIVE MEDICINE
TABLE 12             ALLOGENEIC PRODUCTS MARKET, BY REGION, 2017–2024 (USD BILLION)
TABLE 13             CELL-BASED AUTOLOGOUS REGENERATIVE MEDICINE
TABLE 14             AUTOLOGOUS PRODUCTS MARKET, BY REGION, 2017–2024 (USD BILLION)
TABLE 15             FEW OF THE COMMERCIALIZED TISSUE-ENGINEERED PRODUCTS
TABLE 16             REGENERATIVE MEDICINE MARKET FOR TISSUE-ENGINEERED PRODUCTS,
BY REGION, 2017–2024 (USD BILLION)
TABLE 17             FEW OF THE COMMERCIALIZED GENE THERAPY PRODUCTS
TABLE 18             REGENERATIVE MEDICINE MARKET FOR GENE THERAPY PRODUCTS,
BY REGION, 2017–2024 (USD BILLION)
TABLE 19             REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2017–2024 (USD BILLION)
TABLE 20             REGENERATIVE MEDICINE MARKET FOR MUSCULOSKELETAL DISORDERS,
BY REGION, 2017–2024 (USD BILLION)
TABLE 21             REGENERATIVE MEDICINE PRODUCTS COMMERCIALIZED FOR THE TREATMENT OF ACUTE & CHRONIC WOUNDS
TABLE 22             REGENERATIVE MEDICINE MARKET FOR WOUND CARE, BY REGION,
2017–2024 (USD BILLION)
TABLE 23             NUMBER OF CANCER PATIENTS, BY TYPE, 2012–2030
TABLE 24             INDICATIVE LIST OF COMMERCIALIZED REGENERATIVE CELL-BASED IMMUNOTHERAPIES FOR THE TREATMENT OF CANCER
TABLE 25             REGENERATIVE MEDICINE MARKET FOR ONCOLOGY, BY REGION,
2017–2024 (USD BILLION)
TABLE 26             REGENERATIVE MEDICINE MARKET FOR OCULAR DISORDERS,
BY REGION, 2017–2024 (USD BILLION)
TABLE 27             REGENERATIVE MEDICINE MARKET FOR DIABETES, BY REGION,
2017–2024 (USD BILLION)
TABLE 28             REGENERATIVE MEDICINE MARKET FOR OTHER APPLICATIONS,
BY REGION, 2017–2024 (USD BILLION)
TABLE 29             REGENERATIVE MEDICINE MARKET, BY REGION, 2017–2024 (USD BILLION)
TABLE 30             NORTH AMERICA: REGENERATIVE MEDICINE MARKET, BY COUNTRY,
2017–2024 (USD BILLION)
TABLE 31             NORTH AMERICA: REGENERATIVE MEDICINE MARKET, BY TYPE,
2017–2024 (USD BILLION)
TABLE 32             NORTH AMERICA: CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS MARKET, BY TYPE, 2017–2024 (USD BILLION)
TABLE 33             NORTH AMERICA: REGENERATIVE MEDICINE, BY APPLICATION,
2017–2024 (USD BILLION)
TABLE 34             PRODUCTS WITH RMAT DESIGNATION (AS OF 2018)
TABLE 35             US: REGENERATIVE MEDICINE MARKET, BY TYPE, 2017–2024 (USD BILLION)
TABLE 36             US: CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS MARKET,
BY TYPE, 2017–2024 (USD BILLION)
TABLE 37             US: REGENERATIVE MEDICINE MARKET, BY APPLICATION,
2017–2024 (USD BILLION)
TABLE 38             CANADA: REGENERATIVE MEDICINE MARKET, BY TYPE, 2017–2024 (USD BILLION)
TABLE 39             CANADA: CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS MARKET,
BY TYPE, 2017–2024 (USD BILLION)
TABLE 40             CANADA: REGENERATIVE MEDICINE MARKET, BY APPLICATION,
2017–2024 (USD BILLION)
TABLE 41             RESEARCH FUNDING EUROPEAN OVERVIEW
TABLE 42             EUROPE: REGENERATIVE MEDICINE MARKET, BY COUNTRY,
2017–2024 (USD BILLION)
TABLE 43             EUROPE: REGENERATIVE MEDICINE MARKET, BY TYPE, 2017–2024 (USD BILLION)
TABLE 44             EUROPE: CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS MARKET,
BY TYPE, 2017–2024 (USD BILLION)
TABLE 45             EUROPE: REGENERATIVE MEDICINE, BY APPLICATION, 2017–2024 (USD BILLION)
TABLE 46             UK: REGENERATIVE MEDICINE MARKET, BY TYPE, 2017–2024 (USD BILLION)
TABLE 47             UK: CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS MARKET,
BY TYPE, 2017–2024 (USD BILLION)
TABLE 48             UK: REGENERATIVE MEDICINE MARKET, BY APPLICATION,
2017–2024 (USD BILLION)
TABLE 49             GERMANY: REGENERATIVE MEDICINE MARKET, BY TYPE,
2017–2024 (USD BILLION)
TABLE 50             GERMANY: CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS MARKET, BY TYPE, 2017–2024 (USD BILLION)
TABLE 51             GERMANY: REGENERATIVE MEDICINE MARKET, BY APPLICATION,
2017–2024 (USD BILLION)
TABLE 52             FRANCE: REGENERATIVE MEDICINE MARKET, BY TYPE, 2017–2024 (USD BILLION)
TABLE 53             FRANCE: CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS MARKET,
BY TYPE, 2017–2024 (USD BILLION)
TABLE 54             FRANCE: REGENERATIVE MEDICINE MARKET, BY APPLICATION,
2017–2024 (USD BILLION)
TABLE 55             ROE: REGENERATIVE MEDICINE MARKET, BY TYPE, 2017–2024 (USD BILLION)
TABLE 56             ROE: CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS MARKET,
BY TYPE, 2017–2024 (USD BILLION)
TABLE 57             ROE: REGENERATIVE MEDICINE MARKET, BY APPLICATION,
2017–2024 (USD BILLION)
TABLE 58             APAC: REGENERATIVE MEDICINE MARKET, BY COUNTRY,
2017–2024 (USD BILLION)
TABLE 59             APAC: REGENERATIVE MEDICINE MARKET, BY TYPE, 2017–2024 (USD BILLION)
TABLE 60             APAC: CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS MARKET,
BY TYPE, 2017–2024 (USD BILLION)
TABLE 61             APAC: REGENERATIVE MEDICINE MARKET, BY APPLICATION,
2017–2024 (USD BILLION)
TABLE 62             JAPAN: REGENERATIVE MEDICINE MARKET, BY TYPE, 2017–2024 (USD BILLION)
TABLE 63             JAPAN: CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS MARKET,
BY TYPE, 2017–2024 (USD BILLION)
TABLE 64             JAPAN: REGENERATIVE MEDICINE MARKET, BY APPLICATION,
2017–2024 (USD BILLION)
TABLE 65             CHINA: REGENERATIVE MEDICINE MARKET, BY TYPE, 2017–2024 (USD BILLION)
TABLE 66             CHINA: CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS MARKET,
BY TYPE, 2017–2024 (USD BILLION)
TABLE 67             CHINA: REGENERATIVE MEDICINE MARKET, BY APPLICATION,
2017–2024 (USD BILLION)
TABLE 68             AUSTRALIA: REGENERATIVE MEDICINE MARKET, BY TYPE,
2017–2024 (USD BILLION)
TABLE 69             AUSTRALIA: CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS MARKET, BY TYPE, 2017–2024 (USD BILLION)
TABLE 70             AUSTRALIA: REGENERATIVE MEDICINE MARKET, BY APPLICATION,
2017–2024 (USD BILLION)
TABLE 71             ROAPAC: REGENERATIVE MEDICINE MARKET, BY TYPE, 2017–2024 (USD BILLION)
TABLE 72             ROAPAC: CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS MARKET,
BY TYPE, 2017–2024 (USD BILLION)
TABLE 73             ROAPAC: REGENERATIVE MEDICINE MARKET, BY APPLICATION,
2017–2024 (USD BILLION)
TABLE 74             ROW: REGENERATIVE MEDICINE MARKET, BY TYPE, 2017–2024 (USD BILLION)
TABLE 75             ROW: CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS MARKET,
BY TYPE, 2017–2024 (USD BILLION)
TABLE 76             ROW: REGENERATIVE MEDICINE MARKET, BY APPLICATION,
2017–2024 (USD BILLION)

LIST OF FIGURES

FIGURE 1             RESEARCH DESIGN
FIGURE 2             BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION,
AND REGION
FIGURE 3             REGENERATIVE MEDICINE MARKET: BOTTOM-UP APPROACH
FIGURE 4             REGENERATIVE MEDICINE MARKET: TOP-DOWN APPROACH
FIGURE 5             DATA TRIANGULATION METHODOLOGY
FIGURE 6             REGENERATIVE MEDICINE MARKET, BY TYPE, 2019 VS. 2024 (USD BILLION)
FIGURE 7             REGENERATIVE MEDICINE MARKET, BY APPLICATION,
2019 VS. 2024 (USD BILLION)
FIGURE 8             REGENERATIVE MEDICINE MARKET, BY REGION, 2019 VS. 2024 (USD BILLION)
FIGURE 9             GROWING GOVERNMENT INVESTMENTS IN REGENERATIVE MEDICINE RESEARCH TO DRIVE MARKET GROWTH DURING THE FORECAST PERIOD
FIGURE 10          MUSCULOSKELETAL DISORDERS TO DOMINATE THE REGENERATIVE MEDICINE MARKET IN 2019
FIGURE 11          COUNTRIES IN EUROPE TO REGISTER A HIGHER GROWTH RATE DURING THE FORECAST PERIOD   28
FIGURE 12          REGENERATIVE MEDICINE MARKET: DRIVERS, RESTRAINTS, AND OPPORTUNITIES
FIGURE 13          CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS SEGMENT TO DOMINATE THE MARKET IN 2018
FIGURE 14          ONCOLOGY SEGMENT TO REGISTER THE HIGHEST GROWTH IN THE REGENERATIVE MEDICINE MARKET DURING THE FORECAST PERIOD
FIGURE 15          PREVALENCE OF DIABETES, BY REGION, 2015 VS. 2040
FIGURE 16          NORTH AMERICA TO WITNESS THE HIGHEST GROWTH IN THE REGENERATIVE MEDICINE MARKET DURING THE FORECAST PERIOD
FIGURE 17          INVESTMENT LEVELS QUADRUPLED DURING 2010–2016
FIGURE 18          NORTH AMERICA: REGENERATIVE MEDICINE MARKET SNAPSHOT
FIGURE 19          KEY DEVELOPMENTS IN THE REGENERATIVE MEDICINE MARKET
FIGURE 20          REGENERATIVE MEDICINE MARKET RANKING, BY KEY PLAYER, 2018
FIGURE 21          MNM DIVE-VENDOR COMPARISON MATRIX: REGENERATIVE MEDICINE MARKET
FIGURE 22          MNM DIVE-VENDOR COMPARISON MATRIX FOR START-UPS: REGENERATIVE MEDICINE MARKET
FIGURE 23          NOVARTIS: COMPANY SNAPSHOT
FIGURE 24          VERICEL: COMPANY SNAPSHOT
FIGURE 25          INTEGRA LIFESCIENCES: COMPANY SNAPSHOT
FIGURE 26          MIMEDX GROUP: COMPANY SNAPSHOT
FIGURE 27          STRYKER : COMPANY SNAPSHOT
FIGURE 28          WRIGHT MEDICAL: COMPANY SNAPSHOT
FIGURE 29          OSIRIS THERAPEUTICS: COMPANY SNAPSHOT



掲載企業リスト

プレスリリース

プレスリリース

Memo.png当レポートのプレスリリースは発行されておりません。

資料検索

お探しの資料・レポートをキーワードで検索ください。

当サイト内の検索結果が表示されます。調査レポートは英文目次を掲載しているため、英語検索も有効です。
(ブラウザのスクリプトを有効にしないとサーチエンジンが表示されません)

お問い合わせ

2714110_0.jpg
レポートをお探しいたします。
当サイトに掲載されているレポート以外にも幅広くご提案可能です。レポートの内容に関するご質問、ご確認にも回答いたします。お気軽にお問い合わせください。